Issue 1 Anticoagulation Matters:
Surgical Prophylaxis Edition

Hear from A/Prof. Kerry Hitos (Director of the Westmead Research Centre for Evaluation of Surgical Outcomes, USyd), and Prof. Christopher Ward (Clinical haematologist, RNS Hospital), on treatment and management of disease in Australia, such as VTE.

A/Prof. Kerry Hitos describes why Australian researchers have excellent reputations.


Professor Chris Ward: "Where we've still got work to do is in developing the tools for risk assessment".


A "3 bucket" model approach is recommended by A/Prof. Kerry Hitos for assessing VTE risk in surgical patients. 


VTE = venous thromboembolism.

Date of preparation: March 2019. SM_SAN980. SAANZ.ENO.19.01.0069

*Clexane Safety Lock as an automatic safety lock system.

Further information is available on request from Sanofi.


PBS Information: CLEXANE®. General Benefit Antithrombotic agent. Refer to PBS schedule for full information.CLEXANE® with Automatic Safety Lock System. Refer to PBS schedule for full information. CLEXANE® FORTE. This product is not listed on the PBS.

Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.

sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.


Receive future issues of Anticoagulation Matters, compiled specifically for you.


Access patient information and resources on VTE and Clexane®.